Expression of DNA double-strand break repair proteins predicts the response and prognosis of colorectal cancer patients undergoing oxaliplatin-based chemotherapy

Ihara,Keisuke; Yamaguchi,Satoru; Ueno,Nozomi; Tani,Yukiko; Shida,Yosuke; Ogata,Hideo; Domeki,Yasushi; Okamoto,Kentaro; Nakajima,Masanobu; Sasaki,Kinro; Tsuchioka,Takashi; Mitomi,Hiroyuki; Kato,Hiroyuki

doi:10.3892/or.2015.4488

Expression of DNA double-strand break repair proteins predicts the response and prognosis of colorectal cancer patients undergoing oxaliplatin-based chemotherapy

Authors:
- Keisuke Ihara
- Satoru Yamaguchi
- Nozomi Ueno
- Yukiko Tani
- Yosuke Shida
- Hideo Ogata
- Yasushi Domeki
- Kentaro Okamoto
- Masanobu Nakajima
- Kinro Sasaki
- Takashi Tsuchioka
- Hiroyuki Mitomi
- Hiroyuki Kato
View Affiliations

Affiliations: Department of Surgical Oncology, Dokkyo Medical University, Mibu, Shimotsuga, Tochigi 321-0293, Japan, Department of Surgical and Molecular Pathology, Dokkyo Medical University, Mibu, Shimotsuga, Tochigi 321-0293, Japan
Published online on: December 16, 2015 https://doi.org/10.3892/or.2015.4488
Pages: 1349-1355

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

DNA intrastrand cross-linking agents such as oxaliplatin induce DNA double-strand breaks (DSBs) during DNA repair and replication. In the present study, we hypothesized that DNA intrastrand cross-linking agents may significantly benefit colorectal cancer patients with deficiencies in DSB repair. Seventy-eight patients with metastatic or recurrent colorectal cancer who had measurable target lesions and who underwent resection for primary colorectal cancer in our institution between April 2007 and March 2013 were included in the present study. The median age was 64.5 years, and the cohort consisted of 49 males and 29 females. The median progression-free survival (PFS) was 10.9 months. The expression of DSB repair proteins such as RAD51 and MRE11 was investigated by immunohistochemistry, and associations between RAD51 and MRE11 expression and clinicopathological factors or chemotherapeutic effect were assessed. MRE11-negative cases and RAD51-negative cases achieved significantly better tumor reduction compared with cases with positive expression. Cases with negative expression of both proteins or negative expression of either protein had significantly longer PFS than cases with positive expression for both proteins. In conclusion, DSB repair protein expression-negative colorectal cancer cases may be more highly sensitive to chemotherapy, and thus DSB repair protein expression may be a useful prognostic indicator for colorectal cancer patients.

View Figures

View References

1	Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol. 22:229–237. 2004. View Article : Google Scholar
2	Yamaguchi S, Ogata H, Katsumata D, Nakajima M, Fujii T, Tsutsumi S, Asao T, Sasaki K, Kuwano H and Kato H: Early serum carcinoembryonic antigen reduction predicts tumor shrinkage and overall survival in colorectal cancer patients with distant metastasis, after primary surgery followed by mFOLFOX6 plus bevacizumab treatment. Hepatogastroenterology. In press.
3	Grothey A, Sargent D, Goldberg RM and Schmoll HJ: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 22:1209–1214. 2004. View Article : Google Scholar : PubMed/NCBI
4	Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol. 26:2013–2019. 2008. View Article : Google Scholar : PubMed/NCBI
5	Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 360:1408–1417. 2009. View Article : Google Scholar : PubMed/NCBI
6	Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, et al: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 349:247–257. 2003. View Article : Google Scholar : PubMed/NCBI
7	Chiu SJ, Lee YJ, Hsu TS and Chen WS: Oxaliplatin-induced gamma-H2AX activation via both p53-dependent and -independent pathways but is not associated with cell cycle arrest in human colorectal cancer cells. Chem Biol Interact. 182:173–182. 2009. View Article : Google Scholar : PubMed/NCBI
8	Asakawa H, Koizumi H, Koike A, Takahashi M, Wu W, Iwase H, Fukuda M and Ohta T: Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins. Breast Cancer Res. 12:R172010. View Article : Google Scholar : PubMed/NCBI
9	Turner N, Tutt A and Ashworth A: Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer. 4:814–819. 2004. View Article : Google Scholar : PubMed/NCBI
10	Chu G: Double strand break repair. J Biol Chem. 272:24097–24100. 1997. View Article : Google Scholar : PubMed/NCBI
11	Gallagher DJ, Konner JA, Bell-McGuinn KM, Bhatia J, Sabbatini P, Aghajanian CA, Offit K, Barakat RR, Spriggs DR and Kauff ND: Survival in epithelial ovarian cancer: A multivariate analysis incorporating BRCA mutation status and platinum sensitivity. Ann Oncol. 22:1127–1132. 2011. View Article : Google Scholar
12	Moynahan ME, Cui TY and Jasin M: Homology-directed DNA repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res. 61:4842–4850. 2001.PubMed/NCBI
13	Stracker TH and Petrini JH: The MRE11 complex: Starting from the ends. Nat Rev Mol Cell Biol. 12:90–103. 2011. View Article : Google Scholar : PubMed/NCBI
14	Williams RS, Williams JS and Tainer JA: Mre11-Rad50-Nbs1 is a keystone complex connecting DNA repair machinery, double-strand break signaling, and the chromatin template. Biochem Cell Biol. 85:509–520. 2007. View Article : Google Scholar : PubMed/NCBI
15	Baumann P and West SC: Role of the human RAD51 protein in homologous recombination and double-stranded-break repair. Trends Biochem Sci. 23:247–251. 1998. View Article : Google Scholar : PubMed/NCBI
16	Slupianek A, Schmutte C, Tombline G, Nieborowska-Skorska M, Hoser G, Nowicki MO, Pierce AJ, Fishel R and Skorski T: BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell. 8:795–806. 2001. View Article : Google Scholar : PubMed/NCBI
17	Takenaka T, Yoshino I, Kouso H, Ohba T, Yohena T, Osoegawa A, Shoji F and Maehara Y: Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer. Int J Cancer. 121:895–900. 2007. View Article : Google Scholar : PubMed/NCBI
18	Piessevaux H, Buyse M, Schlichting M, Van Cutsem E, Bokemeyer C, Heeger S and Tejpar S: Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol. 31:3764–3775. 2013. View Article : Google Scholar : PubMed/NCBI
19	Yoshida M, Goto M, Kii T, Nishitani H, Kawabe S, Kuwakado S, Asaishi K, Miyamoto T and Higuchi K: Retrospective study as first-line chemotherapy combined anti-VEGF antibody with fluoropyrimidine for frail patients with unresectable or metastatic colorectal cancer. Digestion. 87:59–64. 2013. View Article : Google Scholar : PubMed/NCBI
20	Maeda K, Shibutani M, Otani H, Nagahara H, Sugano K, Ikeya T, Kubo N, Amano R, Kimura K, Muguruma K, et al: Low nutritional prognostic index correlates with poor survival in patients with stage IV colorectal cancer following palliative resection of the primary tumor. World J Surg. 38:1217–1222. 2014. View Article : Google Scholar
21	Thompson LH and Schild D: The contribution of homologous recombination in preserving genome integrity in mammalian cells. Biochimie. 81:87–105. 1999. View Article : Google Scholar : PubMed/NCBI
22	Sung P and Robberson DL: DNA strand exchange mediated by a RAD51-ssDNA nucleoprotein filament with polarity opposite to that of RecA. Cell. 82:453–461. 1995. View Article : Google Scholar : PubMed/NCBI
23	Nakanoko T, Saeki H, Morita M, Nakashima Y, Ando K, Oki E, Ohga T, Kakeji Y, Toh Y and Maehara Y: Rad51 expression is a useful predictive factor for the efficacy of neoadjuvant chemoradiotherapy in squamous cell carcinoma of the esophagus. Ann Surg Oncol. 21:597–604. 2014. View Article : Google Scholar :
24	Tsai MS, Kuo YH, Chiu YF, Su YC and Lin YW: Down-regulation of Rad51 expression overcomes drug resistance to gemcitabine in human non-small-cell lung cancer cells. J Pharmacol Exp Ther. 335:830–840. 2010. View Article : Google Scholar : PubMed/NCBI
25	Hannay JA, Liu J, Zhu QS, Bolshakov SV, Li L, Pisters PW, Lazar AJ, Yu D, Pollock RE and Lev D: Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: A role for p53/activator protein 2 transcriptional regulation. Mol Cancer Ther. 6:1650–1660. 2007. View Article : Google Scholar : PubMed/NCBI
26	Giannini G, Rinaldi C, Ristori E, Ambrosini MI, Cerignoli F, Viel A, Bidoli E, Berni S, D'Amati G, Scambia G, et al: Mutations of an intronic repeat induce impaired MRE11 expression in primary human cancer with microsatellite instability. Oncogene. 23:2640–2647. 2004. View Article : Google Scholar : PubMed/NCBI
27	Vilar E, Bartnik CM, Stenzel SL, Raskin L, Ahn J, Moreno V, Mukherjee B, Iniesta MD, Morgan MA, Rennert G, et al: MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res. 71:2632–2642. 2011. View Article : Google Scholar : PubMed/NCBI
28	Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, et al: Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 28:3219–3226. 2010. View Article : Google Scholar : PubMed/NCBI
29	Yamaguchi S, Ogata H, Katsumata D, Nakajima M, Fujii T, Tsutsumi S, Asao T, Sasaki K, Kuwano H and Kato H: MUTYH- associated colorectal cancer and adenomatous polyposis. Surg Today. 44:593–600. 2014. View Article : Google Scholar